WO2017144065A1 - Production industrielle durable de guaïanolides basée sur une culture de tissu d'organe - Google Patents

Production industrielle durable de guaïanolides basée sur une culture de tissu d'organe Download PDF

Info

Publication number
WO2017144065A1
WO2017144065A1 PCT/DK2017/050049 DK2017050049W WO2017144065A1 WO 2017144065 A1 WO2017144065 A1 WO 2017144065A1 DK 2017050049 W DK2017050049 W DK 2017050049W WO 2017144065 A1 WO2017144065 A1 WO 2017144065A1
Authority
WO
WIPO (PCT)
Prior art keywords
basal medium
plant
range
shoots
thapsigargin
Prior art date
Application number
PCT/DK2017/050049
Other languages
English (en)
Inventor
Henrik Toft SIMONSEN
Carmen Quinonero LOPEZ
Franck Michoux
Patricia CORRAL
Original Assignee
University Of Copenhagen
Ipalk Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Copenhagen, Ipalk Sas filed Critical University Of Copenhagen
Publication of WO2017144065A1 publication Critical patent/WO2017144065A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H4/00—Plant reproduction by tissue culture techniques ; Tissue culture techniques therefor
    • A01H4/005—Methods for micropropagation; Vegetative plant propagation using cell or tissue culture techniques
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0025—Culture media for plant cell or plant tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/007—Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes

Definitions

  • the present invention relates to a method of producing complex guaianolides, and in particular guaianolides having a thapsigargin backbone which are characterized with a guaiene backbone and a lactone ring (see Formula I below), herein collectively termed "thapsigargin backbone guaianolides”.
  • Thapsigargin backbone guaianolides and Nortrilobolid backbone guaianolides are a family of complex guaianolides, which can be isolated from plants of the sub-family Apioideae, for example from plants of the genus Thapsia or Laser.
  • Thapsigargin backbone guaianolides are characterized with a guaiene backbone and a lactone ring (see Formula I below).
  • TIB temporary immersion bioreactors
  • Sesquiterpenoids (Ci 5 ) are a large group of specialized metabolites widespread within the genus Thapsia. But it is thaspsigargin and fifteen closely related hexa- and penta- oxigenated guaianolides (herein collectively termed "thapsigargin backbone guaianolides" which are of most interest.
  • hexaoxygenated guaianolides such as thapsigargin and pentaoxygenated guaianolides such as nortrilobolide are potent inhibitors of the SERCA (sarco- endoplasmic reticulum calcium transport ATPase) pump.
  • SERCA sarco- endoplasmic reticulum calcium transport ATPase
  • the irreversible inhibition of SERCA leads to elevated cytoplasmic Ca 2+ levels that induce apoptosis in mammalian cells. As such, they have become powerful tools in the study of Ca 2+ signaling pathways.
  • Table 1 Thapsigargin and similar guaianolides reported within Thapsia. The table is amended from Drew et al [4].
  • Thapsia garganica L. ( Figure 2) in 1978. This bioactive compound is the major constituents of the roots and fruits of this Mediterranean species and currently, all of the commercially available thapsigargin is obtained from fruits and roots of wild populations of 7 ' .garganica. Due to T. garganica difficulty to germinate from seeds and to maintain under greenhouse conditions, Thapslbiza, a Spanish company, is the only company in the world, which has started a small production of T. garganica plants. The reliable and sustainable supply of Thapsia biomass is therefore extremely limited.
  • the present invention provides a method for the production of thapsigargins from in vitro plant material of genius Thapsia with high yields.
  • the advantages of the in vitro propagation methods for Thapsigargin production are many: (i) an in vitro propagation method contributes to the plant's conservation; (ii) an in vitro propagation method ensures a limitless, continuous and uniform supply of product, and is not subject to pests, disasters and seasonal fluctuations; (iii) an in vitro plant material can be cultivated in large bioreactors, and can be induced to overproduce thapsigargins by manipulating environmental conditions; (iv) a tissue culture stage is a prerequisite for current transformation protocols for the ultimate recovery of transgenic plants.
  • the present invention provides a method for the production of thapsigargins from in vitro plant material of genius Thapsia.
  • the invention comprises a temporary immersion bioreactor (TIB) for biomass micropropagation, including means for incorporating chemical inducing agents (salt, metals, organic compounds, hormones, elicitors, etc.) and adequate conditions.
  • TIB temporary immersion bioreactor
  • An object of the present invention is, therefore, to supply the commercial and pharmacological need of thapsigargins from in vitro plant of Thapsia at industrial levels.
  • Another object of the invention is to provide a protocol of micropropagation of the genus Thapsia via direct and indirect organogenesis which offer a viable tool for mass multiplication and germplasm conservation of these rare and threatened medicinal plants.
  • the invention provides methods of producing guaianolides, said methods comprising the steps of
  • the invention also provides methods for producing a pharmaceutical composition, said method comprising the steps of
  • the invention also provides methods for producing a prodrug, said method comprising the steps of
  • Figure 1 Relative potencies of thapsigargin and related analogues [1 ]. Concentration of inhibitor required to elicit 50% of SERCA. The table shows the equipotency between thapsigargin and nortrilobolide.
  • Figure 2 Structure of G-202 [2].
  • Prodrug that comprises thapsigargin linked to an antigen specific for prostate cancer.
  • Figure 3 Retrosynthesis of 2-acetoxytrilobolid (4) from Nortrilobolide (3).
  • Figure 4 a and b, leaflet explants cultured in the basal medium A for 3 months in light conditions; c, in vitro plant cultured in the basal medium B. Subcultures of in vitro T.garganica plants.
  • FIG. 5 Thapsia garganica in vitro plant after 3 weeks cultured in tubes with the basal medium C.
  • Figure 6 Biomass production stages of in vitro Thapsia garganica plants cultured in TIBs with the basal medium B.
  • Figure7 FW increased of Thapsia garganica in vitro shoots after 3 weeks in TIBs cultured with the basal medium B.
  • Figure 8 HPLC profile of the thapsigargin and nortrilobolide extracted from the in vitro plants.
  • FIG. 9 Thapsigargin calibration curve (12, 60, 600, 120 and 1200 mg/L).
  • Figure 10 Nortrilobolide calibration curve (1 1 , 54, 168, 504 and 1075 mg/L).
  • FIG 11 UV-UPLC chromatrogram of T garganica in vitro plant (LC-MS) 230 nm.
  • Thapsia spp. has been used in traditional medicine in the Mediterranean region for thousands of years.
  • the effects of Thapsia spp. are due to the presence of specialized metabolites, such as sesquiterpenoids, which are found in all members of the genus [10].
  • the present invention is based in an efficient micropropagation system, by using temporary immersion bioreactors (TIB), that implies the rapid multiplication of plant material to produce large number of progeny plants and different cultures medias or treatments that enhance significantly the amounts of guaianolides.
  • TIB temporary immersion bioreactors
  • basal medium refers to medium capable of supporting propagation and/or growth of plant tissue, such as plant cells, roots and/or shoots.
  • the basal medium may be an aqueous solution comprising one or more, for example all of the mineral salts, vitamins, organic nitrogen sources and/or carbon sources described herein in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium may comprise other components as described herein e.g. plant hormones, and/or elicitors.
  • elicitors refers to molecules capable of enhancing the production of secondary metabolites with phytoalexinic properties as well as to obtain more insight into the regulation of their biosynthetic pathways.
  • embryogenic callus refers to plant cells, either cultivated on a solid media, or in liquid media, in which case they may be referred to as embryogenic cell suspensions. Both kinds must be capable of producing somatic embryos when placed into contact with specific plant hormones.
  • the term “explant” is the plant material used to produce plant clones from a “mother plant” and can be parts of leaves, of roots, seeds, flowers, stems, bark and buds.
  • the term “explant” is the plant material used to produce plant clones from a “mother plant” and can be parts of leaves, of roots, seeds, flowers, stems, bark and buds.
  • the term "multiplication” is used to refer to plants that are multiplied by cloning the plants themselves. In such manner, a large number of specimens can be obtained, which are identical to each other and to the specimen introduced in vitro at the beginning of the process.
  • organogenic refers to plant material that have the capacity for organogenesis. Organogenesis is the creation of new form and organisation, where previously it was lacking.
  • rooting refers to the process to obtain complete plants, such as shoots with developed roots.
  • shoots refers to plant leaves and stems capable of photosynthesis and usually denotes the presence of at least one shoot meristem.
  • a method of producing guaianolides provides methods for producing guaianolides. Said methods may comprise in vitro propagation of plant tissue of a plant of the subfamily Apioideae, e.g. a plant of the genus Thapsia or the genus Laser. In particular the invention provides methods of producing guaianolides, wherein the methods comprise the steps of
  • tissue which is in the form of embryogenic callus and/or shoots, said tissue being derived from a plant of the subfamily Apioideae, which for example may be any of the plant tissues described herein below in the section "Plant tissue derived from a plant of the subfamily Apioideae”
  • a basal medium B which for example may be performed in any of the manners described herein below in the section "Cultivation in basal medium B", thereby inducing plant shoot micropropagation;
  • step d) optionally isolating produced guaianolides, which for example may be done in any of the manners described herein below in the section "Purification of guaianolides".
  • the method may also comprise additional steps.
  • the methods may comprise an additional step performed after step b., but prior to step d.
  • This step may be referred to as step c), which may comprise or consist of steps c1 ) and/or c2).
  • Said step c1 ) may comprise culturing the plant shoots generated in step b) on or in a basal medium C, which for example may be performed in any of the manners described herein below in the section "Cultivation in basal medium C", thereby inducing root formation.
  • Said step c2) may comprise culturing the plant shoots generated in step b) on or in a basal medium D, E and/or F, which for example may be performed in any of the manners described herein below in the section "Cultivation in basal medium D", “Cultivation in basal medium E” or “Cultivation in basal medium F", thereby increasing the production of secondary metabolites such as guaianolides.
  • Said step c) may comprise steps c1 ) and c2), i.e. culturing the plant shoots generated in step b) on or in a basal medium C and/on or in a basal medium D, E and/or F, as described in any of the aforementioned sections.
  • the embryogenic callus and/or shoots provided in step a) may be obtained by culturing a plant tissue of a plant of the sub-family Apioideae on a basal medium A containing one or more plant growth regulators (PGRs) in any of the manners described herein below in the section "Cultivation on basal medium A".
  • PGRs plant growth regulators
  • the embryogenic callus and/or shoots provided in step a) may be shoots obtained after cultivation in basal medium B.
  • all or a fraction of the shoots obtained may be sub-cultured in fresh basal medium B to obtain even further plant shoots.
  • the embryonic callus and/or shoot are typically obtained by cultivation of plant tissue (e.g. an explant) of a plant of the sub-family Apioideae on basal medium A, however once obtained, embryogenic callus and/or shoots may be micropropagated in basal medium B for many generations.
  • plant tissue e.g. an explant
  • embryogenic callus and/or shoots may be micropropagated in basal medium B for many generations.
  • the plant shoot obtained by micropropagation produces high levels of guaianolides, including thapsigargin backbone guaianolides, such as thapsigargin.
  • the plant shoots obtained by the micropropagation of step b) comprises at least 0.1 mg, preferably at least 0.5 mg, more preferably at least 1 mg, for example at least 5 mg, such as at least 10 mg, for example in the range of 10-15 mg guaianolides per g dry weight plant shoot.
  • the plant shoots obtained by the micropropagation of step b) may comprises at least 0.1 mg, more preferably at least 1 mg, for example at least 5 mg, for example in the range of 5-15 mg thapsigargin per g dry weight plant shoot.
  • the high yield is obtained by cultivating differentiated material (i.e. embryogenic callus and/or shoots) in a temporary immersion bioreactor (TIB).
  • TIB temporary immersion bioreactor
  • embryogenic callus and/or shoots comprises high levels of guaianolides, and the present invention provide means for cultivation of said embryogenic callus and/or shoots in an efficient and industrially relevant manner in a TIB.
  • guaianolides e.g. thapsigargin or other thapsigargin backbone guaianolides
  • guaianolides may be purified from the plant shoots obtained by the micropropagation of step b).
  • the plants obtained after the induction of root formation of step c) comprise at least 1 mg, preferably at least 2 mg, more preferably at least 3 mg more preferably at least 5 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg guaianolides per g dry weight plant.
  • the plants obtained after step c) may comprise at least 1 mg, more preferably at least 3 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg thapsigargin per g dry weight plant.
  • guaianolides e.g. thapsigargin backbone guaianolides, thapsigargin or nortrilobolid
  • guaianolides may be purified from the plant shoots obtained after induction of root formation in step c).
  • the plants obtained after enhancing secondary metabolite production of step c) comprise at least 1 mg, preferably at least 2 mg, more preferably at least 3 mg more preferably at least 5 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg guaianolides per g dry weight plant.
  • the plants obtained after step c) may comprise at least 1 mg, more preferably at least 3 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg thapsigargin per g dry weight plant.
  • guaianolides e.g. thapsigargin backbone guaianolides, thapsigargin or nortrilobolid
  • guaianolides may be purified from the plant shoots obtained after enhancing secondary metabolite production in step c).
  • the plants obtained produces high levels of guaianolides, including thapsigargin backbone guaianolides.
  • the plants obtained after the induction of root formation and enhancing secondary metabolite production of step c) comprise at least 1 mg, preferably at least 2 mg, more preferably at least 3 mg more preferably at least 5 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg guaianolides per g dry weight plant.
  • the plants obtained after step c) may comprise at least 1 mg, more preferably at least 3 mg, yet more preferably at least 10 mg, for example in the range of 10-15 mg thapsigargin per g dry weight plant.
  • guaianolides e.g. thapsigargin backbone guaianolides, thapsigargin or nortrilobolid
  • the method comprises step b) as described above, and step c) as described above.
  • step c) comprises or consists of step c1 ).
  • step c) comprises or consists of step c2).
  • step c) comprises or consists of step c1 ) and step c2).
  • the method may additionally comprise a step prior to step a), comprising culturing plant tissue in basal medium A as described in the section "Cultivation on basal medium A.
  • Step a) is typically useful for establishing or starting a new culture, and can usually be dispensed with once the culture has been initiated for a given plant.
  • Plant tissue derived from a plant of the subfamily Apioideae comprises the step of providing plant tissue derived from a plant of the sub-family Apioideae.
  • Said plant may for example be a plant of the genus Thapsia or said plant may for example be a plant of the genus Laser.
  • the methods comprises cultivating plant tissue, which is embryogenic callus and/or shoot in basal medium B.
  • Said embryogenic callus and/or shoot may originally be obtained from plant tissue taken directly from a plant of the sub-family Apioideae.
  • Said plant tissue may be from any useful part of a plant of the sub-family Apioideae, e.g.
  • plant tissue taken directly from a plant of the sub-family Apioideae to be used as starting material for generating embryogenic callus and/or shoots may also be referred to as "explant".
  • said plant tissue is part of leaves of a plant of the sub- family Apioideae, e.g. of the genus Thapsia or the genus Laser.
  • the plant from which the plant tissue is obtained may have been propagated by any useful method, e.g. it may have been propagated in the field, in nature or by in vitro propagation, e.g. by cultivation in basal medium B and/or basal medium C and/or basal medium D, E and/or F described below.
  • the plant of the sub-family Apioideae may for example be a plant of the genus Thapsia or the genus Laser.
  • the plant of the genus Thapsia may be any plant of said genus.
  • said plant of the genus Thapsia may be selected from the group consisting of: T. leucotricha, T. tenuifolia, Tgarganica, T. gymnesica, T. transtagana, T. thapsioides, T. gummifera, T. smittii, T. asclepium, T. scabra, T. maxima, T. villosa, T. minor and T. laciniata.
  • the plant of the genus Laser may be any plant of said genus.
  • said plant of the genus Laser may be selected from the group consisting of: L. trilobum, L.siler, L. aquilegifolium, Laser divaricatum, Laser rechingeri and L. cordifolium.
  • the plant from which the plant tissue is obtained may be a wild-type plant or a genetically modified plant. While wild-type plants can be used in the present methods to produce guaianolides (e.g. thapsigargin backbone guaianolides, thapsigargin or nortrilobolid), genetically modified plants may be designed as is known in the art to further increase the yields, e.g by increasing biomass or increasing guaianolide levels. Methods of genetically modifying plants are known in the art and include random mutagenesis and subsequent selection of plants with the desired characteristics, nuclear transformation, chloroplast transformation. The plants can also be modified as is known in the art so that production of guaianolides (e.g. thapsigargin backbone guaianolides, thapsigargin or nortrilobolid) is transient. Cultivation on basal medium A
  • the invention relates to methods involving culturing embryogenic callus and/or shoots in basal medium B (see herein below).
  • Said embryogenic callus and/or shoots may be obtained by culturing plant tissue taken directly from a plant of the sub-family Apioideae, e.g. by culturing an explant of a plant of the sub-family Apioideae in basal medium A.
  • the basal medium A is a medium capable of supporting growth of a plant.
  • the basal medium A comprises one or more plant growth regulators (PGRs).
  • PGRs plant growth regulators
  • the PGRs present together are capable of inducing embryogenic callus and/or shoot formation.
  • cultivation on the basal medium A preferably results in formation of embryogenic callus and/or shoot formation.
  • the basal medium A comprises at least one plant growth regulator which is an auxin.
  • the auxin is capable of inducing differentiation.
  • the basal medium A comprises the plant growth regulator 2,4- Dichlorophenoxyacetic acid (2,4-D).
  • concentration of 2,4-D in the first basal medium may be in the range of 0.01 -3.0 mg 1 , for example in the range of 0.05 - 1 mg 1 , such as approximately 0.1 mg 1 .
  • the basal medium A comprises a plant growth regulator, which is a cytokinin.
  • Said cytokinin may for example be selected from the group consisting of phenyl-N'- (1 ,2,3-thiadiazol-5-yl) urea (TDZ) and 6-benzylaminopurine (BAP).
  • the basal medium A may comprise the plant growth regulator phenyl-N'-(1 ,2,3-thiadiazol-5-yl) urea (TDZ) or 6-benzylaminopurine (BAP).
  • TDZ plant growth regulator phenyl-N'-(1 ,2,3-thiadiazol-5-yl) urea
  • BAP 6-benzylaminopurine
  • the concentration of TDZ or BAP in the basal medium A may be in the range of 0.1 -5.0 mg 1 , for example in the range of 0.1 to 2 mg 1 , such as in the range of 0.1 -1 mg 1 .
  • the basal medium A in general also comprises additional components promoting plant growth and/or viability.
  • the basal medium A may contain typical ingredients of plant basal media.
  • the basal medium A may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source".
  • the basal medium A may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium A may also further comprise one or more organic nitrogen sources, including any of the organic nitrogen sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium A may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”. Media for cultivation of plant material are known in the art.
  • the basal medium A may be a conventional plant growth medium, such as MS further comprising sugar and the PGRs described above.
  • the basal medium A may be in solid of semisolid phase, i.e. it may be a gel.
  • the basal medium A may also comprise a gelling agent, e.g. agar.
  • the basal medium A may comprise in the range of 1 to 50 g 1 , preferably in the range of 1 to 25 g 1 , such as in the range of 1 to 15 g 1 , for example in the range of 3 to 13 g 1 , such as in the range of 5 to 9 g 1 , for example approximately 7 g 1 , such as 7 g 1 gelling agent, e.g. agar.
  • the pH of the basal medium A may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation on the basal medium A is preferably performed for a time period sufficient to allow embryogenic callus and/or shoot formation. Typically, this may require several days, thus the cultivation may be for at least 1 week, preferably for at least 1 month, more preferably at least two months, for example in the range of 2 to 5 months, such as for approximately 3 months.
  • Cultivation on the basal medium A may be at any useful temperature allowing growth and/or differentiation of the plant tissue.
  • the temperature may be room temperature, e.g. a temperature in the range of 15 to 30 °C, such as in the range of 20 to 26 °C, for example in the range of 22 to 24 °C.
  • the cultivation on the basal medium A is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium A may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day. Exposure to light may aid in differentiation into embryogenic callus and/or shoots.
  • the methods of the invention may comprise cultivation of embryogenic callus, and/or shoots in a basal medium B.
  • Said embryogenic callus and/or shoots may be obtained by cultivation of a plant tissue obtained from a plant of the genus Thapsia on a basal medium A as described above.
  • the new embryogenic callus and/or shoots obtained from cultivation on the basal medium A may be cultured in a basal medium B in an amount sufficient to ensure shoots micropropagation.
  • the embryogenic callus and/or shoots are in general organogenic plant material.
  • the embryogenic callus and/or shoots may be derived from a culture of embryogenic callus and/or shoots in basal medium B, in which case the step of cultivation in basal medium B also could be regarded as a subcultivation.
  • Basal medium B is capable of supporting plant shoot micropropagation.
  • the basal medium B comprises at least one auxin and at least one cytokinin.
  • the at least one auxin and at least one cytokinin are preferably together capable of promoting direct or indirect shoot formation.
  • cultivation on or in the basal medium B preferably results in plant shoot micropropagation.
  • Cytokinins are a group of chemicals that primarily influence cell division and shoot formation but also have roles in delaying cell senescence, are responsible for mediating auxin transport throughout the plant, and affect internodal length and leaf growth.
  • Cytokinins comprise a class of growth regulators, they particulary stimulate protein synthesis and participate in cell cycle control. It is perhaps for this reason that they can promote the maturation of chloroplasts and delay the senescence of detached leaves. The effect of cytokinins is most noticeable in tissue cultures where they are used, often together with auxins, to stimulate cell division and control morphogenesis. Added to shoot culture media, these compounds overcome apical dominance and release lateral bud from dormancy.
  • the cytokinin may be any natural or artificial cytokinin, for example a cytokinin belonging to the adenine-type or the phenylurea-type.
  • the cytokinin is selected from the group consisting of kinetin, zeatin, 6-benzylaminopurine (BAP), diphenylurea (Ph 2 Urea), thidiazuron (TDZ), and isopentiladenina (2-lp).
  • BAP 6-benzylaminopurine
  • Ph 2 Urea diphenylurea
  • TDZ thidiazuron
  • the cytokin may also be a derivative of any of the aforementioned, which has cytokinin activity
  • the basal medium B comprises the cytokinin 6- benzylaminopurine (BAP).
  • BAP cytokinin 6- benzylaminopurine
  • concentration of BAP in the basal medium B is in the range of 0.1 -5.0 mg 1 , for example in the range of 1 to 2 mg 1 , such as approximately 1 .5 mg/L.
  • auxins are compounds that positively influence cell enlargement, bud formation and root initiation. They also promote the production of other hormones and in conjunction with cytokinins, they control the growth of stems, roots, fruits and convert stems into flowers.
  • Said auxin may be any useful auxin, such as the naturally occurring auxins.
  • the auxin may be selected from the group consisting of 4-chloro-indoleacetic acid (4-CPA), phenylacetic acid (PAA), indole-3-butyric acid (IBA), chloroindole-3-acetic acid (CI-IAA) and indole-3-acetic acid (IAA).
  • the auxin may also be a synthetic auxin, e.g.
  • auxin selected from the group consisting of 1 -naphthaleneacetic acid (NAA), 3,6-dichloroanisic acid (dicamba), 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and 2,4-dichlorophenoxyacetic acid (2,4-D).
  • the basal medium B may comprise the auxin 1 - naphthaleneacetic acid (NAA).
  • NAA auxin 1 - naphthaleneacetic acid
  • concentration of NAA in the basal medium B is in the range of 0.01 -3.0 mg I for example in the range of 0.1 -1 mg 1 .
  • the basal medium B in general also comprises additional components promoting plant shoot formation and micropropagation.
  • the basal medium B may contain typical ingredients of plant basal media.
  • the basal medium B may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium B may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium B may also further comprise one or more organic nitrogen sources, including any of the organic nitrogen sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium B may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • Media for cultivation of plant material are known in the art.
  • the basal medium B may be a conventional plant growth medium, such as MS further comprising sugar and the cytokinin(s) and auxin(s) described above.
  • the pH of the basal medium B may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation in basal medium B is generally performed using a method involving temporary immersion in basal medium B.
  • the cultivation in basal medium B may be performed using an immersion bioreactor, e.g. a temporary immersion bioreactor.
  • Temporary immersion bioreactors are also known as temporary liquid immersion culture systems.
  • temporary liquid immersion culture systems e.g. temporary immersion bioreactors or TIBs
  • TIBs temporary immersion bioreactors
  • Etienne & Berthouly (2002) Plant Cell, Tissue and Organ Culture 69, 215-231 , Hanhineva & Karenlampi (2007) BMC Biotechnology 7, 1 1 -23, and also from Ducos et al (2007) In Vitro Cellular & Developmental Biology - Plant 43: 652-659 and any of these systems may be used with the invention except that basal medium B should be used.
  • the temporary immersion bioreactor may comprise at least two vessels, one containing the embryogenic callus and/or the plant shoots and one for the liquid basal medium B, wherein the vessels are coupled together in a manner allowing the flow of the liquid media from one vessel to the other.
  • This flux may for example be driven by a pump or by gravity through a see-saw movement.
  • the temporary immersion bioreactor will ensure alternation between immersion of the embryogenic callus and/or shoots in the basal medium B and leaving the embryogenic callus and/or shoots without medium.
  • the embryogenic callus and/or shoots are immersed in sufficient amounts of basal medium B to completely cover the embryogenic callus and/or shoots.
  • the immersion may take place every 2 to 10 hours, e.g.
  • the immersion may last for in the range of 1 to 15 min., such as in the range of 2 to 10 mins, for example for in the range of 2 to 5 min, such as for approximately 3 min.
  • a fraction of plant shoots are transferred to fresh basal medium B.
  • Said plant shoots may have been manipulated to remove dead tissue or to separate individual shoots. This can be done manually or automatically.
  • Cultivation in basal medium B is preferably performed for a time period sufficient to allow sufficient plant shoot micropropagation.
  • the incubation may be for a time sufficient to obtain at least 2x, preferably at least 3x, more preferably at least 4x, such as at least 5x, for example approximately 5x increase in biomass. Typically, this may require several days, thus the cultivation may be for at least 1 week, preferably for at least 2 weeks, for example at least 3 weeks, such as for approximately 3 weeks.
  • Cultivation in the basal medium B may be at any useful temperature allowing micropropagation of plant shoots.
  • the temperature may be in the range of 15 to 30 °C, such as in the range of 20 to 28 °C, for example in the range of 22 to 26 °C, such as at approximately 24 °C.
  • the cultivation in the basal medium B is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium B may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day. Exposure to light may aid shoot micropropagation.
  • the methods of the invention may comprise cultivation of plant shoots on or in a basal medium C, e.g. cultivation of the shoots obtained after micropropagation in basal medium B.
  • the methods of the invention may comprise a step c), which may comprise or consist of step c1 ) of cultivating the shoots obtained in step b) in basal medium C, Preferably cultivation in basal medium C results in root formation.
  • Cultivation in basal medium C may involve temporary immersion of the plant shoots in basal medium C, Alternatively, the cultivation may be performed on basal medium C in gel or liquid form. In this case, individual single shoots may be transferred to basal medium C and incubated to allow root formation.
  • the basal medium C is capable of supporting growth of plants and comprises at least one auxin.
  • the auxin is capable of inducing formation of roots.
  • the basal medium C may comprise one auxin, which is capable if inducing formation of roots.
  • cultivation on the basal medium C preferably results in formation of roots.
  • the basal medium C comprises one or more auxins selected from the group consisting of 2,4-Dichlorophenoxyacetic acid (2,4-D), indole-3-butyric acid (IBA), 1 - naphthaleneacetic acid (NAA) and indole-3-acetic acid (IAA).
  • basal medium C may comprise an auxin selected from the group consisting of NAA, IAA and IBA.
  • the basal medium C may comprise IBA.
  • concentration of IBA in the basal medium C may be in the range of 0.1 -8.0 mg 1 , for example in the range of 1 to 5 mg 1 .
  • the basal medium C may comprise NAA. Typically, the concentration of NAA in the basal medium C may be in the range of 0.1 -8.0 mg 1 , for example in the range of 1 to 5 mg 1 .
  • the basal medium C may comprise IAA. Typically, the concentration of IAA in the basal medium C may be in the range of 0.1 -8.0 mg 1 , for example in the range of 1 to 5 mg 1 .
  • the basal medium C in general also comprises additional components promoting plant growth and/or viability.
  • the basal medium C may contain typical ingredients of plant basal media.
  • the basal medium C may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium C may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium C may also further comprise one or more amino acid(s), including any of the amino acid(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium C may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source". Frequently, the basal medium C comprises a lower level of mineral salts than basal medium A and basal medium B. The low level of mineral salts may aid in induction of root formation.
  • Media for cultivation of plant material are known in the art.
  • the basal medium C may be a conventional plant growth medium further comprising an auxin as described above. Since the basal medium C frequently contains low levels of mineral salts, the basal medium C may also be a diluted conventional plant growth medium, such as diluted MS, e.g. 40-60% MS in water, further comprising sugar and an auxin as described above.
  • the basal medium C may be in solid or semisolid phase, i.e. it may be a gel.
  • the basal medium C may also comprise a gelling agent, e.g. agar.
  • the basal medium C may comprise in the range of 1 to 50 g 1 , preferably in the range of 1 to 25 g 1 , such as in the range of 1 to 15 g 1 , for example in the range of 3 to 13 g 1 , such as in the range of 5 to 9 g 1 , for example approximately 7 g 1 , such as 7 g 1 gelling agent, e.g. agar.
  • Cultivation in basal medium C may also be performed using a method involving temporary immersion in basal medium C.
  • the cultivation in basal medium C may be performed using an immersion bioreactor, e.g. a temporary immersion bioreactor.
  • Temporary immersion bioreactors are also known as temporary liquid immersion culture systems. Any of the methods for temporary immersion described herein above in the section "Cultivation in basal medium B" may also be employed for cultivation involving temporary immersion in basal medium C.
  • the embryogenic callus and/or shoots are immersed in sufficient amounts of basal medium C to completely cover the embryogenic callus and/or shoots.
  • the immersion may take place every 2 to 10 hours, e.g. every 4 to 8 hours, e.g. approximately every 6 hour, and the immersion may last for in the range of 1 to 15 min., such as in the range of 2 to 10 mins, for example for in the range of 2 to 5 min, such as for approximately 3 min.
  • the pH of the basal medium C may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation on the basal medium C is preferably performed for a time period sufficient to allow root formation. Typically, this may require several days, thus the cultivation may be for at least 1 week, preferably for at least 2 weeks, more preferably at least 1 month, such as for approximately 1 month.
  • Cultivation in the basal medium C may be at any useful temperature allowing micropropagation of plant shoots. Typically, the temperature may be in the range of 15 to 30 °C, such as in the range of 20 to 28 °C, for example in the range of 22 to 26 °C, such as at approximately 24 °C.
  • the cultivation in the basal medium C is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium C may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day.
  • the methods of the invention may comprise cultivation of plant shoots on or in a basal medium D., e.g. cultivation of the shoots obtained after micropropagation in basal medium B.
  • the methods of the invention may comprise a step c), which may comprise or consist of step c2) of cultivating the shoots obtained in step b) in basal medium D.
  • a step c) of cultivating the shoots obtained in step b) in basal medium D Preferably cultivation in basal medium D results in increased production of thapsigargins.
  • basal medium D may involve temporary immersion of the plant shoots in basal medium D.
  • the basal medium D composition is based on "basal medium B" further comprising an elicitor.
  • Elicitors are compounds that stimulate any type of plant defense, thereby promoting secondary metabolism. These secondary metabolites include terpenes, steroids, phenolics and alkaloids.
  • Elicitors, abiotic or biotic include: AgN03, AICI3, CaCI2, CdCI2, CoCI2, CuCI2, HgCI2, KCI, MgS04, NiS04, VOS04, Zn, microbial enzymes, bacterial lysates and polysaccharides from microorganism cell walls, polysaccharides arising from pathogen degradation of the plant cell wall, intracellular proteins, and small molecules synthesized by the plant including plant hormones such as jasmonates or salicylic acid.
  • the basal medium D is capable of promoting production of secondary metabolites such as thapsigargins.
  • the basal medium D also comprises an elicitor belonging to the abiotic or biotic types.
  • the at least one auxin and at least one cytokinin are preferably together capable of promoting direct or indirect shoot formation
  • the elicitor is selected from the biotic group: microbial enzymes, bacterial lysates, polysaccharides from microorganism cell walls, polysaccharides arising from pathogen degradation of the plant cell wall, intracellular proteins, and small molecules synthesized by the plant including plant hormones such as ujasmonates or salicylic acid.
  • Jasmonate and its derivatives are lipid-based hormones that regulate a wide range of processes in plants, ranging from growth and photosynthesis to reproductive development. Jasmonates are oxylipins, i.e. derivatives of oxygenated fatty acids. Jasmonate itself can be further metabolized into active or inactive derivatives. Methyl jasmonate (MeJA or MeJ) is a volatile compound. Jasmonate conjugated with isoleucine results in JA-lle. Decarboxylation of jasmonate yields cis-jasmone. In some embodiments, the elicitor is a jasmonate.
  • the jasmonate may be selected from the group of: jasmonate, methyl jasmonate (MeJ), JA-lle and cis-jasmone.
  • the elicitor is methyl jasmonate.
  • the concentration of MeJ in the basal medium D is in the range of 1 - 1000 ⁇ , for example in the range of 10 to 600 ⁇ , such as approximately 400 ⁇ .
  • the basal medium D may contain typical ingredients of plant basal media. Frequently, the basal medium D may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”. The basal medium D may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”. The basal medium D may also further comprise one or more amino acid(s), including any of the amino acid(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”. The basal medium D may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium D may be in solid or semi-solid phase, i.e. it may be in the form of a gel.
  • the basal medium D may also comprise a gelling agent, e.g. agar.
  • the basal medium D may comprise in the range of 1 to 50 g/L, preferably in the range of 1 to 25 g/L, such as in the range of 1 to 15 g/L, for example in the range of 3 to 13 g/L, such as in the range of 5 to 9 g/L, for example approximately 7 g/L gelling agent, e.g. agar.
  • Cultivation in basal medium D may also be performed using a method involving temporary immersion in basal medium D.
  • the cultivation in basal medium D may be performed using an immersion bioreactor, e.g. a temporary immersion bioreactor (TIB).
  • Temporary immersion bioreactors are also known as temporary liquid immersion culture systems. Any of the methods for temporary immersion described herein above in the section "Cultivation in basal medium B" may also be employed for cultivation involving temporary immersion in basal medium D.
  • the shoots are immersed in sufficient amounts of basal medium D to completely cover the shoots.
  • the immersion may take place every 2 to 10 hours, e.g. every 4 to 8 hours, e.g. approximately every 6 hour, and the immersion may last for in the range of 1 to 15 min, such as in the range of 5 to 10 min, for example for in the range of 2 to 5 min, such as for approximately 3 min.
  • the pH of the basal medium D may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation on the basal medium D is preferably performed for a time period sufficient to increase thapsigargin production. In some embodiments, this may require several days, thus the cultivation may be for at least 5 days, preferably for at least 10 days, more preferably at least 15 days, even more preferably at least 18 days, such as for approximately 18 days.
  • Cultivation in the basal medium D may be at any useful temperature allowing micropropagation of plant shoots and increase of thapsigarginproduction.
  • the temperature may be in the range of 15 to 30 °C, such as in the range of 20 to 28 q C, for example in the range of 22 to 26°C, such as at approximately 24 °C.
  • the cultivation in the basal medium D is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium D may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day.
  • the methods of the invention may comprise cultivation of plant shoots on or in a basal medium E, e.g. cultivation of the shoots obtained after micropropagation in basal medium B.
  • the methods of the invention may comprise a step c) comprising or consisting of step c2) of cultivating the shoots obtained in step b) in basal medium E,
  • cultivation in basal medium E results in increased production of thapsigargins.
  • Cultivation in basal medium E may involve temporary immersion of the plant shoots in basal medium E.
  • the cultivation may be performed on basal medium E in gel or liquid form.
  • basal medium E is preferably devoid of elicitors such as hormones and is thus capable of increasing thapsigargin production without any elicitor or hormone in the medium.
  • the basal medium E in general comprises additional components promoting plant viability and thapsigargin production.
  • the basal medium E may contain typical ingredients of plant basal media.
  • the basal medium E may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source".
  • the basal medium E may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium E may also further comprise one or more amino acid(s), including any of the amino acid(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium E may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium E similar to basal medium C, comprises a lower level of mineral salts than basal medium A, B and basal medium D. Without being bound by theory, it is hypothesized that the low level of mineral salts may aid in increasing thapsigargin production.
  • the basal medium E may also be a diluted conventional plant growth medium, such as diluted MS, e.g. 40-60% MS in water.
  • the basal medium E may be in solid or semi-solid phase, i.e. it may be in the form of a gel.
  • the basal medium E may also comprise a gelling agent, e.g. agar.
  • the basal medium E may comprise in the range of 1 to 50 g/L, preferably in the range of 1 to 25 g/L, such as in the range of 1 to 15 g/L, for example in the range of 3 to 13 g/L, such as in the range of 5 to 9 g/L, for example approximately 7 g/L, such as 7 g/L gelling agent, e.g. agar.
  • Cultivation in basal medium E may also be performed using a method involving temporary immersion in basal medium E.
  • the cultivation in basal medium E may be performed using an immersion bioreactor, e.g. a temporary immersion bioreactor.
  • Temporary immersion bioreactors are also known as temporary liquid immersion culture systems. Any of the methods for temporary immersion described herein above in the section "Cultivation in basal medium B" may also be employed for cultivation involving temporary immersion in basal medium E.
  • the shoots are immersed in sufficient amounts of basal medium E to completely cover the shoots.
  • the immersion may take place every 2 to 10 hours, e.g. every 4 to 8 hours, e.g. approximately every 6 hour, and the immersion may last for in the range of 1 to 15 min., such as in the range of 5 to 10 min, for example for in the range of 2 to 5 min, such as for approximately 3 min.
  • the pH of the basal medium E may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation on the basal medium E is preferably performed for a time period sufficient to allow high amounts of thapsigargins. In some embodiments, this may require several days, thus the cultivation may be for at least 5 days, preferably for at least 10 days, more preferably at least 15 days, even more preferably at least 18 days, such as for approximately 18 days.
  • Cultivation in the basal medium E may be at any useful temperature allowing viability of plant shoots and high thapsigargin production. Typically, the temperature may be in the range of 15 to 30 °C, such as in the range of 20 to 28 °C, for example in the range of 22 to 26 °C, such as at approximately 24 °C.
  • the cultivation in the basal medium E is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium E may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day.
  • the methods of the invention may comprise cultivation of plant shoots on or in a basal medium F, e.g. cultivation of the shoots obtained after micropropagation in basal medium B.
  • the methods of the invention may comprise a step c) comprising or consisting of step c2) of cultivating the shoots obtained in step b) in basal medium F.
  • cultivation in basal medium F results in increased production of thapsigargins.
  • Cultivation in basal medium F may involve temporary immersion of the plant shoots in basal medium F, Alternatively, the cultivation may be performed on basal medium F in gel or liquid form. In this case, individual single shoots may be transferred to basal medium F and incubated to allow increased production of thapsigargins.
  • the basal medium F is capable of increasing thapsigargin production and comprises at least one elicitor. Preferably, the elicitor is capable of promoting secondary metabolism, especially thapsigargins. As shown in the examples, in the hands of the inventors cultivation on basal medium F resulted in the highest production of thapsigargins.
  • Basal medium F comprises an elicitor.
  • Elicitors are compounds that stimulate any type of plant defense, thereby promoting secondary metabolism. These secondary metabolites include terpenes, steroids, phenolics and alkaloids.
  • Elicitors, abiotic or biotic include: AgN03, AICI3, CaCI2, CdCI2, CoCI2, CuCI2, HgCI2, KCI, MgS04, NiS04, VOS04, Zn, microbial enzymes, bacterial lysates and polysaccharides from microorganism cell walls, polysaccharides arising from pathogen degradation of the plant cell wall, intracellular proteins, and small molecules synthesized by the plant including plant hormones such as jasmonates or salicylic acid.
  • the basal medium F is capable of promoting production of secondary metabolites such as thapsigargins.
  • the basal medium F also comprises an elicitor belonging to the abiotic or biotic types.
  • the elicitor is selected from the biotic group: microbial enzymes, bacterial lysates, polysaccharides from microorganism cell walls, polysaccharides arising from pathogen degradation of the plant cell wall, intracellular proteins, and small molecules synthesized by the plant including plant hormones such as ujasmonates or salicylic acid.
  • Jasmonate and its derivatives are lipid-based hormones that regulate a wide range of processes in plants, ranging from growth and photosynthesis to reproductive development. Jasmonates are oxylipins, i.e. derivatives of oxygenated fatty acids. Jasmonate itself can be further metabolized into active or inactive derivatives. Methyl jasmonate (MeJA or MeJ) is a volatile compound. Jasmonate conjugated with isoleucine results in JA-lle. Decarboxylation of jasmonate yields cis-jasmone.
  • the elicitor is a jasmonate.
  • the jasmonate may be selected from the group of: jasmonate, methyl jasmonate (MeJ), JA-lle and cis-jasmone.
  • the elicitor is methyl jasmonate.
  • the concentration of MeJ in the basal medium F is in the range of 1 - 1000 ⁇ , for example in the range of 10 to 600 ⁇ , such as approximately 400 ⁇ .
  • the basal medium F in general comprises additional components promoting plant viability and thapsigargin production.
  • the basal medium F may contain typical ingredients of plant basal media.
  • the basal medium F may comprise one or more mineral salt(s), including any of the mineral salt(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium F may also further comprise one or more vitamin(s), including any of the vitamin(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium F may also further comprise one or more amino acid(s), including any of the amino acid(s) described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium F may also further comprise one or more carbon sources, including any of the carbon sources described herein below in the section "Mineral salt, vitamin, organic nitrogen source and carbon source”.
  • the basal medium F similar to basal medium C and E, comprises a lower level of mineral salts than basal medium A, B and basal medium D. Without being bound by theory, it is hypothesized that the low level of mineral salts may aid in increasing thapsigargin production.
  • the basal medium F may also be a diluted conventional plant growth medium, such as diluted MS, e.g. 40-60% MS in water.
  • the basal medium F may be in solid or semi-solid phase, i.e. it may be in the form of a gel.
  • the basal medium E may also comprise a gelling agent, e.g. agar.
  • the basal medium F may comprise in the range of 1 to 50 g/L, preferably in the range of 1 to 25 g/L, such as in the range of 1 to 15 g/L, for example in the range of 3 to 13 g/L, such as in the range of 5 to 9 g/L, for example approximately 7 g/L, such as 7 g/L gelling agent, e.g. agar.
  • Cultivation in basal medium F may also be performed using a method involving temporary immersion in basal medium F.
  • the cultivation in basal medium F may be performed using an immersion bioreactor, e.g. a temporary immersion bioreactor.
  • Temporary immersion bioreactors are also known as temporary liquid immersion culture systems. Any of the methods for temporary immersion described herein above in the section "Cultivation in basal medium B" may also be employed for cultivation involving temporary immersion in basal medium F.
  • the shoots are immersed in sufficient amounts of basal medium F to completely cover the shoots.
  • the immersion may take place every 2 to 10 hours, e.g. every 4 to 8 hours, e.g. approximately every 6 hour, and the immersion may last for in the range of 1 to 15 min, such as in the range of 5 to 10 min, for example for in the range of 2 to 5 min, such as for approximately 3 min.
  • the pH of the basal medium F may be adjusted before cultivation, for example it may be adjusted to a pH in the range of 5 to 7, such as to a pH in the range of 5.5 to 6.5, for example to a pH of approximately 5.8.
  • Cultivation on the basal medium F is preferably performed for a time period sufficient to allow high amounts of thapsigargins. In some embodiments, this may require several days, thus the cultivation may be for at least 5 days, preferably for at least 10 days, more preferably at least 15 days, even more preferably at least 18 days, such as for approximately 18 days.
  • Cultivation in the basal medium F may be at any useful temperature allowing viability of plant shoots and high thapsigargin production.
  • the temperature may be in the range of 15 to 30 °C, such as in the range of 20 to 28 °C, for example in the range of 22 to 26 °C, such as at approximately 24 °C.
  • the cultivation in the basal medium F is preferably performed at least partly under light, e.g. it may be performed under lamps providing a regulated photoperiod of light/darkness.
  • the cultivation is performed under a light/darkness circle with alternating light periods and darkness periods, for example in the range of 8 to 20 hours light periods interrupted by in the range of 4 to 16 hours dark periods.
  • cultivation on basal medium F may involve exposure to light for at least 8 hours, such as in the range of 8 to 20 hours, for example in the range of 12 to 18 hours per day.
  • the basal medium A, B, C, D, E and F may comprise mineral salt(s), vitamin(s), organic nitrogen sources and/or carbon sources. Furthermore, the basal medium A, B, C, D, E and F may also comprise other compounds, such as organic compounds, hormones and elicitors.
  • the organic nitrogen source may be any organic compound comprising at least one N-atom.
  • the nitrogen source may be one or more amino acids, e.g. glycine.
  • the basal medium A, B, C, D, E and/or F may comprise in the range of 1 to 10 mg/L, such as in the range of 1 to 5 mg/L, for example in the range of 1 to 3 mg/L, such as approximately 2 mg/L glycine.
  • the carbon source may be any organic compound, however typically the carbon source is a sugar.
  • the carbon source is sucrose.
  • the basal medium A, B, C, D, E and/or F may comprise in the range of 2 to 5%, such as in the range of 2 to 4%, for example approximately 3% (w/w) sucrose.
  • the basal medium A, B, C, D, E and/or F may also comprise mineral salt(s) and/or vitamin(s).
  • the basal medium A, B and D may comprise more mineral salts than basal medium C, E or F for example basal medium C, E or F may comprise in the range of 40 to 60%, such as approximately 50% of the mineral salts of basal medium B.
  • the basal medium A and/or B and/or D may comprise CoCI 2 .6H 2 0, for example in the range of 0.01 to 0.1 mg/L, such as in the range of 0.01 to 0.05 mg/L, for example in the range of 0.02 to 0.03 mg/L, such as approximately 0.025 mg/L CoCI 2 .6H 2 0.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the basal medium A and/or B and/or D may comprise CuS0 4 .5 H 2 0, for example in the range of 0.01 to 0.1 mg/L, such as in the range of 0.01 to 0.05 mg/L, for example in the range of 0.02 to 0.03 mg/L, such as approximately 0.025 mg/L CuS0 4 .5 H 2 0.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise FeNaEDTA, for example in the range of 5 to 200 mg/L, such as in the range of 10 to 100 mg/L, for example in the range of 20 to 60 mg/L, such as approximately 37 mg/L FeNaEDTA.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise H 3 B0 3 , for example in the range of 1 to 20 mg/L, such as in the range of 1 to 10 mg/L, for example in the range of 4 to 8 mg/L, such as approximately 6 mg/L H 3 B0 3 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise Kl, for example in the range of 0.1 to 10 mg/L, such as in the range of 0.1 to 5 mg/L, for example in the range of 0.5 to 2 mg/L, such as approximately 0.8 mg/L Kl.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise MnS0 4 H 2 0, for example in the range of 1 to 200 mg/L, such as in the range of 5 to 100 mg/L, for example in the range of 10 to 30 mg/L, such as approximately 17 mg/L MnS0 4 H 2 0.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise Na 2 Mo0 4 .2 H 2 0, for example in the range of 0.1 to 1 mg/L, such as in the range of 0.1 to 0.5 mg/L, for example in the range of 0.2 to 0.3 mg/L, such as approximately 0.25 mg/L Na 2 Mo0 4 .2 H 2 0.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise ZnS0 4 .7 H 2 0, for example in the range of 1 to 20 mg/L, such as in the range of 3 to 15 mg/L, for example in the range of 5 to 10 mg/L, such as approximately 8.6 mg/L ZnS0 4 .7 H 2 0.
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D and/or F may comprise CaCI 2 , for example in the range of 50 to 2000 mg/L, such as in the range of 100 to 1000 mg/L, for example in the range of 200 to 600 mg/L, such as approximately 332 mg/L CaCI 2 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D and/or F may comprise KH 2 P0 4 , for example in the range of 10 to 2000 mg/L, such as in the range of 50 to 1000 mg/L, for example in the range of 100 to 300 mg/L, such as approximately 170 mg/L KH 2 P0 4 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise KN0 3 , for example in the range of 100 to 20000 mg/L, such as in the range of 500 to 10000 mg/L, for example in the range of 1000 to 3000 mg/L, such as approximately 1900 mg/L KN0 3 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D and/or F may comprise MgS0 4 , for example in the range of 10 to 2000 mg/L, such as in the range of 50 to 1000 mg/L, for example in the range of 100 to 300 mg/L, such as approximately 180 mg/L MgS0 4 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A and/or B and/or D may comprise NH 4 N0 3 , for example in the range of 100 to 20000 mg/L, such as in the range of 500 to 10000 mg/L, for example in the range of 1000 to 3000 mg/L, such as approximately 1650 mg/L NH 4 N0 3 .
  • the basal medium C and/or E and/or F may comprise 40 to 60%, such as approximately 50% of aforementioned concentrations.
  • the first, second and/or third and/or basal medium A, B, C, D, E and/or F may comprise myo- Inositol, for example in the range of 10 to 500 mg/L, such as in the range of 30 to 300 mg/L, for example in the range of 50 to 200 mg/L, such as approximately 100 mg/L myo-lnositol.
  • the first, second and/or third and/or basal medium A, B, C, D, E and/or F may comprise Nicotinic acid, for example in the range of 0.05 to 5 mg/L, such as in the range of 0.1 to 2 mg/L, for example in the range of 0.2 to 0.8 mg/L, such as approximately 0.5 mg/L Nicotinic acid.
  • the first, second and/or third and/or basal medium A, B, C, D, E and/or F may comprise pyridoxine HCI, for example in the range of 0.05 to 5 mg/L, such as in the range of 0.1 to 2 mg/L, for example in the range of 0.2 to 0.8 mg/L, such as approximately 0.5 mg/L pyridoxine HCI.
  • the first, second and/or third and/or basal medium A, B, C, D, E and/or F may comprise Thiamine, for example in the range of 0.1 to 5 mg/L, such as in the range of 0.3 to 3 mg/L, for example in the range of 0.5 to 2 mg/L, such as approximately 1 mg/L Thiamine.
  • the basal medium A, B, C, D, E and/or F do not comprise additional components apart from the components defined herein and water.
  • Guaianolides The invention relates to methods for production of guaianolides.
  • Said guaianolide may for example be a hexaoxygenated guaianolide or a pentaoxygenated guaianolide.
  • the guaianolide may be a guaianolide comprising a thapsigargin backbone.
  • guaianolides are also referred to as thapsigargin backbone guaianolides herein.
  • the guaianolide is a guaianolide comprising a core structure of formula I:
  • Ri may be any of the Ri groups listed in table 1 herein above.
  • R 2 may be any of the R 2 groups listed in table 1 herein above.
  • the guaianolide may be a thapsigargin backbone guaianolide. Thapsigargin backbone guaianolides comprises a core structure of formula I.
  • the thapsigargin backbone guaianolide may be a compound of formula I, wherein
  • R 2 may for example be -H, such as any of the R 2 groups listed in table 1 herein above
  • the guaianolide may be a nortrilobolide backbone guaianolide.
  • Nortrilobolide backbone guaianolides are compounds of formula I, wherein R is -H, and
  • the guaianolide may be selected from the group of guaianolides mentioned in Table 1 herein above.
  • the guaianolide may be selected from the group consisting of thapsigargin, nortrilobolide, thapsivillosin I and thapsivillosin C.
  • the guaianolide may be selected from the group of guaianolides shown in figure 1 .
  • the guaianolide is nortrilobolide, the structure of which is provided in figure 1 .
  • the guaianolide is thapsigargin.
  • the structure of thapsigargin is provided in figure 1 .
  • the guaianolides may be purified according to any useful method.
  • the purification may involve freeze drying the biomass, e.g. the plant shoots obtained in step b) and/or the plants obtained in step c), grinding the freeze dried material to a powder, followed by extraction with a solvent such as ethanol.
  • the mixture may be centrifuged and the guaianolides purified from the supernatant by chromatography.
  • the methods of purification may also involve freezing involve lyophilising the biomass, e.g. the plant shoots obtained in step b) and/or the plants obtained in step c), homogenising the lyophilised biomass with a solvent in a bead mill, followed by centrifugation to obtain a crude extract and purification of the components of the crude extract for example as described in Ollivier A et al. 2013 Ollivier, A. 2013; J Chromatogr B Analyt Technol Biomed Life Sci.; 926: 6- 20].
  • a method of producing a pharmaceutical composition or a prodrug in one embodiment the invention relates to a method for producing a prodrug, said method comprising the steps of
  • the prodrug may thus comprise or consist of a guaianolide, a linker and a peptide.
  • Said guaianolide may be any of the guaianolides described herein above in the section "Guaianolides”, and in particular in may be thapsigargin.
  • the linker may for example be an alkyl, such as d- 12 -alkyl, for example CM 2 linear alkyl, such as linear octyl.
  • the linker is preferably attached to the R 2 group of formula I.
  • the prodrug may be a guaianolide of formula I, wherein the R 2 group is attached to a linker, and the linker is attached to said peptide.
  • the linker may be attached to the guaianolide by substitution of R 2 with a substituent of the formula
  • Useful methods for preparing the prodrug starting from a guaianolide, e.g. thapsigargin are also described in US8772226.
  • the peptide of the present invention may be any peptide cleavable by a PSMA protein or derivative thereof.
  • the peptide may comprise the sequence Asp-Glu- Glu-Glu-Glu.
  • the peptide may comprise the sequence Asp-Glu.
  • the peptide of the present invention may be any peptide cleavable by a PSA protein or a derivative thereof.
  • the peptide may be any of the peptides having one of the following SEQ ID numbers in US 8772226: SEQ ID NO:42, SEQ ID NO:43,SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51 , SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO: 55, or SEQ ID NO:56.
  • the peptide of the present invention may be any peptide cleavable by a hK2 protein or a derivative thereof.
  • the peptide may be any of the peptides having one of the following SEQ ID numbers in US 8772226: SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 , SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 , SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27
  • the peptide further comprises a capping group attached to the N- terminus of the peptide, wherein the capping group inhibits endopeptidase activity.
  • the capping group is selected from the group consisting of acetyl, morpholinocarbonyl, benzyloxycarbonyl, glutaryl, and succinyl substituents.
  • the prodrug may be any of the prodrugs described in US8772226, such as any of the compounds described therein, In a preferred embodiment the prodrug is G-202, the structure of which is shown in figure 2.
  • Example 1 The invention is further illustrated by the following examples, which however should not be construed as being limiting for the invention.
  • Example 1
  • leaves explant that were harvested from a Thapsia garganica stock plant growing under greenhouse conditions (University of Copenhagen, Denmark). The leaves were washed to remove loose dirt and placed in 0,5% NaOCI for 15 min to thoroughly remove the surface decontamination agent, the plant material was washed three times with sterile water in a laminar flow.
  • Leaflet explants were aseptically transferred to petri dishes (90 mm) containing 25 mL MS nutrient medium supplemented with 30 g 1 sucrose and 7 g 1 agar.
  • Leaflet explants were placed with de abaxial surface directly on the medium.
  • a combination of auxins (0.01 -3.0 mg ⁇ 1 2,4-D, e.g.
  • 0.1 mg ⁇ 1 2,4-D and cytokinins (0.1 -5.0 mg I "1 TDZ or BAP, e.g. 0.1 , 0.5 or 1 mg 1 TDZ or BAP) were used to induce cellular differentiation.
  • the PH of all media was adjusted to 5.8 before autoclaving at 121 °C and 103 kPa for 20 min.
  • the explants were placed in a growth room (22-24 °C) fitted with cool white fluorescent lamps automated to provide a photoperiod of 16h light (15 ⁇ m "2 s "1 ) and 8 h darkness or 24 h darkness. These treatments had resulted in callus, embryos and shoots elicitation ( Figure 5a and 5b).
  • T.garganica shoots, buds and callus that had regenerated from the leaflet explants were transferred to a micropropagation fresh medium containing MS nutrient medium supplemented with 30 g 1 sucrose and 7 g 1 agar and a combination of auxins (0.5 mg/L NAA) and cytokinins (1 ,5 mg/L BAP) to induce shoots multiplication.
  • All regenerated shoots (Figure 5c) derived directly or indirectly from explant were left to multiply and grow in culture vessels with solid media or in temporary immersion bioreactors (TIB) with liquid media to use them as a highly regenerative continuous system.
  • Plant shoots cultivated in TIBs can be harvested or subcultured after being cultivated in temporary immersion bioreactors (TIB) for 3 weeks with a 5-fold increase of biomass (FW) of about 500% ( Figure 7 and 8).
  • TIB temporary immersion bioreactors
  • the plants clusters of shoots are separated into individual shoots
  • 2-4 g of individual shoot bases are inoculated on TIBs with fresh liquid subculture medium containing 200 mL MS nutrient supplemented with 30 g 1 sucrose and a combination of auxins (0.5 mg/L 1 -Naphthaleneacetic acid (NAA) ) and cytokinins (1 .5 mg/L 6-Benzylaminopurine (BAP)) to induce multiplication (basal medium B) .
  • auxins 0.5 mg/L 1 -Naphthaleneacetic acid (NAA)
  • BAP 6-Benzylaminopurine
  • Basal medium C IAA mg Thapsigargin/g DW mg Nortrilobolid/g DW
  • Thapsigargins produced from the culture of T. garganica in vitro plants after micropropagation in basal medium B and D, E and/or F as described above, were quantitatively assayed by employing high performance liquid chromatography (HPLC). The identity of these molecules has also been confirmed using a LC-MS method. Plant material and thapsigargins extraction
  • T.garganica in vitro plants were collected from the growth chamber in order to be analyzed.
  • the samples were weighted (fresh weight) and frozen in a -80 °C refrigerator.
  • the frozen tissues were dried in a freeze drier (LABCONCO FreeZone 2.5 plus) for 48 hours.
  • the completely dried tissues were weighted to determine the dry weights and ground into fine powders.
  • About 0.05 g of the powders of each sample were placed into brown Eppendorfs and extracted with 1 .5 mL EtOH 70% under agitation overnight (25 °C). The mixtures were then centrifuged (13000 rpm) for 10 min. 1 mL of the supernatant underwent evaporation by speed vacuum.
  • the extracts were resuspended in 250 ⁇ MeOH 80% (concentration x4). The extracts were then filtered through a 0.45 ⁇ filter, and placed into 1 .5 mL vials and kept in a -20 °C refrigerator until HPLC analysis.
  • Standard solution Standard solutions of thapsigargin and nortrilobolide were prepared in the range 12-1200 mg/L and 1 1 -1007 mg/L respectively, corresponding to the concentration range of the plant extracts.
  • Analytical high performance liquid chromatography (HPLC) system consisted of a quaternary pump (JASCO-2089 Plus pump), a thermoregulated autosampler set at 4°C (Intelligent autosampler JASCO AS-2059) and a PDA detector (UV/VIS detector JASCO MD-2018 Plus). Column temperature was regulated at 30 ° C. Separation of compounds was achieved on a Luna C18 column (5 ⁇ , 4.6 mm X 25 cm) (Phenomenex, USA). The flow rate was set at 0.5 mL/min and the mobile phases consisted of A: water+0.01 % o-phosphoric acid, B: acetonitrile+0.01 % o-phosphoric acid.
  • the binary gradient elution scheme as follows:
  • Eluant B 0.01 % o-phosphoric acid + Acetonitrile (ACN)
  • ACN Acetonitrile
  • the data provided are an average of 18 Thapsia samples grown in basal medium B in TIBs.
  • Table 2 shows Thapsigargin and Nortrilobolid quantification in undifferentiated cell cultures and in embryogenic cell cultures prepared essentially as described in international patent application WO/2015/082978. It is clear that the undifferentiated cell cultures and embryogenic cell cultures produces very low amounts of both Thapsigargin and Nortrilobolid, whereas plant shoots produces both compounds in significant amounts.
  • Wild plants of T. garganica have a concentration of thapsigargin of 0.2%— 1 .2% of the dry weight of the roots and 0.7%— 1 .5% of the dry weight of the ripe fruits, whilst the dried stems and leaves contain a total concentration of 0.1 %-0.5% and 0.1 % respectively [12].
  • the in vitro plant tissue contained about 1 ,22 mg/g DW of thapsigargin and about 6,71 mg/g DW of nortrilobolide representing around the 0.12% of thapsigargin and 0.67% of nortrilobolide of the dry weight of the in vitro leaves and stems (average 18 plants).
  • Eluant B 0.1% formic acid + Acetonitrile (ACN)
  • ACN Acetonitrile
  • the PDA swept wavelength from 200 to 400 nm with a 2.4 resolution.
  • Mass spectra were obtained in positive and negative modes, using an electrospray ionization (ESI) source on a triple quadripole instrument (Waters Acquity) in full scan (50 to 2000 m/z).
  • the mass conditions were as follows, capillary voltage: 3000V, cone voltages: 30 and 60V, desolvatation temperature: 450 q C, source Temp: 150°C, gaz flow cone: 50 l/min, desolvatation gas: 800 l/min.
  • FIGS 10 to 1 1 it can be shown the mass spectra of the different peaks.
  • Thapsivillosin I at 30 V exhibits a major [M-H] " fragment at m/z 605.5 while at 60 V the major [M-H] " fragment is m/z 651 .5 which matches with a formic acid adduct m/z 649 + 46 [M-H] "
  • the major [M-H] " fragment is at m/z 663.5 and in 60 V the major [M-H] " fragment is 709.5 also due to a formic acid adduct 664 + 46 [M-H] " .
  • the demand of thapsigargins will increase in the next decade given its potential medical application as a chemotherapeutic prodrug.
  • the present invention provides an alternative source for the production of thapsigargins.
  • the future need of these molecules can be met by our plant tissue culture that, thanks of the HPLC analyses, has been proved.
  • the invention may for example be as defined in the following items.
  • a method of producing guaianolides comprising the steps of
  • basal medium B comprising at least one auxin and at least one cytokinin which together are capable of inducing plant shoot micropropagation, thereby inducing plant shoot micropropagation;
  • cytokinin is natural or artificial cytokinin belonging to the adenine-type or the phenylurea-type.
  • the basal medium B comprises the cytokinin 6- benzylaminopurine (BAP).
  • the basal medium B comprises an auxin selected from the group consisting of 4-chloro-indoleacetic acid, phenylacetic acid (PAA), indole-3-butyric acid and indole-3-acetic acid and 1 - naphthaleneacetic acid (NAA), 2,4-dichlorophenoxyacetic acid.
  • PAA phenylacetic acid
  • NAA 1 - naphthaleneacetic acid
  • 2,4-dichlorophenoxyacetic acid 2,4-dichlorophenoxyacetic acid
  • the basal medium B comprises the auxin 1 - naphthaleneacetic acid (NAA).
  • NAA auxin 1 - naphthaleneacetic acid
  • the embryogenic callus and/or shoots provided in step a) are obtained by culturing a plant tissue of a plant of the sub-family Apioideae on a basal medium A comprising one or more plant growth regulators (PGRs) capable of inducing embryogenic callus and/or shoot formation, thereby inducing embryogenic callus, and/or shoot formation.
  • PGRs plant growth regulators
  • the basal medium A comprise a plant growth regulator, which is an auxin capable of inducing differentiation.
  • the basal medium A comprises the plant growth regulator 2,4-Dichlorophenoxyacetic acid (2,4-D).
  • the basal medium A comprises a plant growth regulator, which is a cytokinin selected from the group consisting of phenyl-N'-(1 ,2,3-thiadiazol-5-yl) urea (TDZ) and BAP.
  • a plant growth regulator which is a cytokinin selected from the group consisting of phenyl-N'-(1 ,2,3-thiadiazol-5-yl) urea (TDZ) and BAP.
  • step c) performed after step b) and prior to step d), said step c) comprising or consisting of step c1 ) and/or step c2), wherein
  • step c1 is a step of culturing the plant shoots generated in step b) on or in a basal medium C comprising at least one auxin capable of inducing formation of roots, thereby inducing root formation, and/or
  • step c2) is a step of culturing the plant shoots generated in step b) on or in
  • a basal medium D comprising at least one auxin and at least one cytokinin and at least one elicitor capable of promoting production of secondary metabolites such as thapsigargins; and/or
  • a basal medium F comprising at least one elicitor capable of promoting production of secondary metabolites such as thapsigargins. 1 1 .
  • the basal medium C and/or D comprises one or more auxins selected from the group consisting of indole-3- butyric acid (IBA), 1 - naphthaleneacetic acid (NAA) and indole-3-acetic acid (IAA).
  • the basal medium C and/or F comprises mineral salt(s), wherein the level of mineral salts in basal medium C and/or F is 40 to 60% of the level of mineral salts in basal medium B.
  • the elicitor is an abiotic or biotic elicitor such as AgN0 3 , AICI 3 , CaCI 2 , CdCI 2 , CoCI 2 , CuCI 2 , HgCI 2 , KCI, MgS0 4 ,
  • NiS0 4 , VOS0 4 , Zn microbial enzymes, bacterial lysates, cell wall polysaccharides derived from microorganisms, polysaccharides derived from pathogen degradation of the plant cell wall, intracellular proteins, or small molecules synthesized by the plant, for example plant hormones such as jasmonates or salicylic acid.
  • elicitor is selected from jasmonate, methyl jasmonate (MeJ), JA-lle and cis-jasmone.
  • step c1 and/or c2
  • said culturing of step c1 ) and/or c2) involves temporary immersion in basal medium C, and/or temporary immersion in basal medium D, and/or temporary immersion in basal medium E, and/or temporary immersion in basal medium F.
  • the plant of the subfamily Apioideae is a plant of the genus Laser or the genus Thapsia.
  • said plant of the subfamily Apioideae is a plant of the genus Thapsia selected from the group consisting of: T. leucotricha, T. tenuifolia, T.garganica, T. gymnesica, T. transtagana, T. thapsioides, T. gummifera, T. smittii, T. asclepium, T. scabra, T. maxima, T. villosa, T. minor and T. laciniata.
  • said plant of the subfamily Apioideae is a plant of the genus Laser selected from the group consisting of: L trilobum, L.siler, L. aquilegifolium, Laser divaricatum, Laser rechingeri and L. cordifolium
  • the method comprises purifying one or more guaianolides from the plant shoots obtained in step b) or from the plants obtained in step c).
  • the guaianolide comprises a core structure of formula I:
  • guaianolide is any of the guaianolides mentioned in Table 1 .
  • the guaianolide is thapsigargin or nortrilobolide.
  • the method comprises the step of purifying thapsigargin from the plant shoots obtained in step b) or from the plants obtained in step c), c1 ) and/or c2).
  • a method for producing a pharmaceutical composition comprising the steps of i) preparing guaianolides by the method according to any one of the preceding items ii) formulating said thapsigargin into a pharmaceutical composition.
  • a method for producing a prodrug comprising the steps of
  • guaianolide is a guaianolide as defined in any one of items 33 to 34.
  • the peptide comprises or consists of the sequence Asp-Glu-Glu-Glu-Glu.
  • the prodrug is G-202.
  • plant tissue derived from a plant of the sub-family Apioideae wherein said plant tissue is embryogenic callus and/or shoots b. culturing said embryogenic callus, and/or shoots in a manner involving temporary immersion in basal medium B comprising at least one auxin and at least one cytokinin which together are capable of inducing plant shoot micropropagation, thereby inducing plant shoot micropropagation.
  • basal medium B comprising at least one auxin and at least one cytokinin which together are capable of inducing plant shoot micropropagation, thereby inducing plant shoot micropropagation.

Abstract

La présente invention concerne un procédé de production de guaïanolides complexes par une plante du genre Thapsia. L'invention comprend un bioréacteur à immersion temporaire (BIT) et des conditions de culture pour la micropropagation en masse de Thapsia spp. L'invention est avantageuse en ce qu'elle peut être utilisée pour produire de grandes quantités de biomasse de Thapsia spp tout en appliquant à ladite plante des conditions appropriée à la production de quantités significatives de guaïanolides, notamment, sans s'y limiter des thapsigargines. Ce procédé est une nouvelle plateforme de production pour fournir ces molécules d'intérêt commercial à un niveau industriel. En même temps, l'invention concerne également un protocole de micropropagation de Thapsia par organogenèse directe et indirecte en tant qu'outil de conservation de cette plante médicinale importante.
PCT/DK2017/050049 2016-02-26 2017-02-24 Production industrielle durable de guaïanolides basée sur une culture de tissu d'organe WO2017144065A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201670113 2016-02-26
DKPA201670113 2016-02-26

Publications (1)

Publication Number Publication Date
WO2017144065A1 true WO2017144065A1 (fr) 2017-08-31

Family

ID=58410063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2017/050049 WO2017144065A1 (fr) 2016-02-26 2017-02-24 Production industrielle durable de guaïanolides basée sur une culture de tissu d'organe

Country Status (1)

Country Link
WO (1) WO2017144065A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151757A (zh) * 2019-02-26 2019-08-23 沈锋 一种化合物作为asph的酶活抑制剂的应用
CN113402529A (zh) * 2021-06-23 2021-09-17 南京中医药大学 三聚愈创木烷型倍半萜类化合物及其制备方法和应用
US11299700B1 (en) 2021-02-19 2022-04-12 Acequia Biotechnology, Llc Bioreactor containers and methods of growing hairy roots using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
WO2015082978A1 (fr) 2013-12-02 2015-06-11 Phyton Holdings, Llc Production de thapsigargines par culture en suspension de cellules de thapsia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
WO2015082978A1 (fr) 2013-12-02 2015-06-11 Phyton Holdings, Llc Production de thapsigargines par culture en suspension de cellules de thapsia

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, T.B. ET AL.: "Thapsigargin-From Thapsia L. to Mipsagargin", MOLECULES, vol. 20, no. 4, 2015, pages 6113 - 6127, XP055380863, DOI: doi:10.3390/molecules20046113
ANDREWS, S.P. ET AL.: "Design and total synthesis of unnatural analogues of the subnanomolar SERCA inhibitor thapsigargin", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 5, no. 9, 2007, pages 1427 - 1436
BALL, M. ET AL.: "Total synthesis of thapsigargin, a potent SERCA pump inhibitor", ORGANIC LETTERS, vol. 9, no. 4, 2007, pages 663 - 666
BHARAT SINGH ET AL: "Plant terpenes: defense responses, phylogenetic analysis, regulation and clinical applications", 3 BIOTECH, vol. 5, no. 2, 29 April 2014 (2014-04-29), DE, pages 129 - 151, XP055380608, ISSN: 2190-572X, DOI: 10.1007/s13205-014-0220-2 *
CHRISTENSEN, S.; A. ANDERSEN; U. SMITT: "Fortschritte der Chemie organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products", 1997, SPRINGER, article "Sesquiterpenoids from Thapsia species and medicinal chemistry of the thapsigargins", pages: 129 - 167
CHU; SMITH; FELDING; BARAN: "Scalable Synthesis of (-)-Thapsigargin", ACS CENT SCI, vol. 3, no. 1, pages 47 - 51
DAMIAN PAUL DREW ET AL: "Guaianolides in apiaceae: perspectives on pharmacology and biosynthesis", PHYTOCHEMISTRY REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 8, no. 3, 19 May 2009 (2009-05-19), pages 581 - 599, XP019752726, ISSN: 1572-980X, DOI: 10.1007/S11101-009-9130-Z *
DATABASE PUBCHEM COMPOUND 1 June 2005 (2005-06-01), "Compound Summary for CID 446378: Thapsigargin", accession no. 46378
DATABASE PUBCHEM COMPOUND 28 April 2006 (2006-04-28), "Compound Summary for CID 6439396: AC1O5RL5", accession no. 439396
DOAN NHU THI QUYNH ET AL: "Targeting thapsigargin towards tumors", STEROIDS, vol. 97, 24 July 2014 (2014-07-24), pages 2 - 7, XP029150293, ISSN: 0039-128X, DOI: 10.1016/J.STEROIDS.2014.07.009 *
DOAN, N.T.Q. ET AL.: "Chemo-and Regioselective Functionalization of Nortrilobolide: Application for Semisynthesis of the Natural Product 2-Acetoxytrilobolide", JOURNAL OF NATURAL PRODUCTS, vol. 78, no. 6, 2015, pages 1406 - 1414, XP055213014, DOI: doi:10.1021/acs.jnatprod.5b00333
DOAN, N.T.Q. ET AL.: "Targeting thapsigargin towards tumors", STEROIDS, vol. 97, 2015, pages 2 - 7, XP029150293, DOI: doi:10.1016/j.steroids.2014.07.009
DREW, D.P. ET AL.: "Guaianolides in apiaceae: perspectives on pharmacology and biosynthesis", PHYTOCHEMISTRY REVIEWS, vol. 8, no. 3, 2009, pages 581 - 599, XP019752726, DOI: doi:10.1007/s11101-009-9130-z
DUCOS ET AL., IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY - PLANT, vol. 43, 2007, pages 652 - 659
ETIENNE H ET AL: "Temporary immersion systems in plant micropropagation", PLANT CELL, TISSUE AND ORGAN CULTURE, SPRINGER, NL, vol. 69, no. 3, 1 June 2002 (2002-06-01), pages 215 - 231, XP002463450, ISSN: 0167-6857, DOI: 10.1023/A:1015668610465 *
ETIENNE; BERTHOULY, PLANT CELL, TISSUE AND ORGAN CULTURE, vol. 69, 2002, pages 215 - 231
HANHINEVA; KARENLAMPI, BMC BIOTECHNOLOGY, vol. 7, 2007, pages 11 - 23
JAGER, A.K. ET AL.: "Somatic embryogenesis in cell cultures of Thapsia garganica", PLANT CELL REPORTS, vol. 12, no. 9, 1993, pages 517 - 520, XP002737703
MAKUNGA, N.P.; A.K. JAGER; J. VAN STADEN: "An improved system for the in vitro regeneration of Thapsia garganica via direct organogenesis-influence of auxins and cytokinins", PLANT CELL, TISSUE AND ORGAN CULTURE, vol. 82, no. 3, 2005, pages 271 - 280, XP019268616
MAKUNGA, N.P.; A.K. JAGER; J. VAN STADEN: "Improved in vitro rooting and hyperhydricity in regenerating tissues of Thapsia garganica L", PLANT CELL, TISSUE AND ORGAN CULTURE, vol. 86, no. 1, 2006, pages 77 - 86, XP019409361, DOI: doi:10.1007/s11240-006-9100-8
MAKUNGA, N.P.; A.K. JAGER; J. VAN STADEN: "Micropropagation of Thapsia garganica--a medicinal plant", PLANT CELL REP, vol. 21, no. 10, 2003, pages 967 - 73, XP055178818, DOI: doi:10.1007/s00299-003-0623-8
NOKWANDA P MAKUNGA ET AL: "An improved system for the in vitro regeneration of Thapsia garganica via direct organogenesis - influence of auxins and cytokinins", PLANT CELL, TISSUE AND ORGAN CULTURE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 82, no. 3, 1 September 2005 (2005-09-01), pages 271 - 280, XP019268616, ISSN: 1573-5044 *
NOKWANDA P MAKUNGA: "GENETIC TRANSFORMATION AND MICROPROPAGATION OF THAPSIA GARGANICA L.- A MEDICINAL PLANT", 1 November 2003 (2003-11-01), XP055380910, Retrieved from the Internet <URL:http://researchspace.ukzn.ac.za/xmlui/bitstream/ handle/10413/10057/Makunga _Nokwanda_P_2003.pdf? sequence=1> [retrieved on 20170613] *
OLLIVIER, A., J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI., vol. 926, 2013, pages 6 - 20
SMITT, U.W. ET AL.: "Comparative studies in phytochemistry and fruit anatomy of Thapsia garganica and T. transtagana, Apiaceae (Umbelliferae", BOTANICAL JOURNAL OF THE LINNEAN SOCIETY, vol. 117, no. 4, 1995, pages 281 - 292, XP009109771, DOI: doi:10.1006/bojl.1995.0019
TRINE BUNDGAARD ANDERSEN ET AL: "Thapsigargin-From Thapsia L. to Mipsagargin", MOLECULES, vol. 20, no. 4, 8 April 2015 (2015-04-08), pages 6113 - 6127, XP055380863, DOI: 10.3390/molecules20046113 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151757A (zh) * 2019-02-26 2019-08-23 沈锋 一种化合物作为asph的酶活抑制剂的应用
US11299700B1 (en) 2021-02-19 2022-04-12 Acequia Biotechnology, Llc Bioreactor containers and methods of growing hairy roots using the same
CN113402529A (zh) * 2021-06-23 2021-09-17 南京中医药大学 三聚愈创木烷型倍半萜类化合物及其制备方法和应用
CN113402529B (zh) * 2021-06-23 2022-04-15 南京中医药大学 三聚愈创木烷型倍半萜类化合物及其制备方法和应用

Similar Documents

Publication Publication Date Title
El Tahchy et al. Effects of sucrose and plant growth regulators on acetylcholinesterase inhibitory activity of alkaloids accumulated in shoot cultures of Amaryllidaceae
Shohael et al. Application of bioreactor system for large-scale production of Eleutherococcus sessiliflorus somatic embryos in an air-lift bioreactor and production of eleutherosides
US10920248B2 (en) Method for mass-producing viniferin using stevioside from cell culture of grapevine tissue
WO2017144065A1 (fr) Production industrielle durable de guaïanolides basée sur une culture de tissu d&#39;organe
Naika et al. Plant regeneration from callus culture of Clematis gouriana Roxb.–A rare medicinal plant
Laurain-Mattar et al. Amaryllidaceae alkaloid accumulation by plant in vitro systems
CA2930767C (fr) Production de thapsigargines par culture en suspension de cellules de thapsia
Suri et al. Plantlet regeneration and bulbil formation in vitro from leaf and stem explants of Curculigo orchioides, an endangered medicinal plant
Thiruvengadam et al. Effect of exogenous polyamines enhances somatic embryogenesis via suspension cultures of spine gourd (Momordica dioica Roxb. ex. Willd.)
Liu et al. Comparison of phytochemical and antioxidant activities in micropropagated and seed-derived Salvia miltiorrhiza plants
Komaraiah et al. Acetylsalicylic acid and ammonium-induced somatic embryogenesis and enhanced plumbagin production in suspension cultures of Plumbago rosea L.
JPH05507629A (ja) イチイの組織培養によるタキソールの生産方法
IL107960A (en) A creature of Azadirchtin
Amini et al. Improvement of in vitro embryo maturation, plantlet regeneration and transformation efficiency from alfalfa (Medicago sativa L.) somatic embryos using Cuscuta campestris extract
KR101467661B1 (ko) 생리활성물질의 함량이 증가된 섬오갈피 부정근의 배양방법
WO2007107803A2 (fr) Procede et milieux modifies pour la culture de calles et de suspensions cellulaires de hypericum perforatum l.
Anitha et al. Reserpine accumulation in NaCl treated calli of Rauvolfia tetraphylla L
US5312740A (en) Process for producing taxol by cell culture of taxus species
Islam et al. Efficient in vitro cultural techniques for seeds germination of Vanda roxburghii
Cristea et al. Soilless cultures for pharmaceutical use and biodiversity conservation
Ahmed et al. In vitro regeneration and improving kaempferol accumulation in blackberry (Rubus fruticosus L.) callus and suspension cultures
El-Sadek et al. Novel application of Spirulina platensis extract as an alternative to the expensive plant growth regulators on Capparis cartilaginea (Decne.)
Tembe et al. Clonal propagation and hydroxycitric acid production from in vitro shoot cultures of Garcinia indica using root suckers as explant
Shohael et al. Effects of Murashige and Skoog medium strength on germination and secondary metabolites production of Eleutherococcus senticosus's somatic embryos in bioreactor.
Sarin et al. In vivo and In vitro estimation of colchicine in Gloriosa superba L. by high pressure liquid chromatography

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17713156

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17713156

Country of ref document: EP

Kind code of ref document: A1